On behalf of the Scientific Planning Committee (SPC), I would like to welcome you to a series of newsletters where we will summarize the latest clinical and real-world evidence in the field of hypertension and reflect on the clinical impact of these data on the management of patients with hypertension.

Every few months we will delve into recent key articles that may impact clinical practice within the general categories of:

1. Epidemiology,
2. Pathophysiology, and
3. Treatment or Pharmacology.

We invite you to interact with this newsletter through polling questions, listen/view short clinical perspectives from our SPC, and click on hyperlinks to the articles for in-depth study.

Prof. Laurent (Chair)

Key articles in Newsletter #1:

• Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 populationrepresentative studies with 104 million participants. NCD Risk Factor Collaboration (NCD-RisC). Lancet. 2021;398(10304):957-980.
• Monotherapy vs. combination treatments of different complexity: A meta-analysis of blood pressure lowering randomized outcome trials. Thomopoulos C, et al. J Hypertens. 2021;39(5):846-855.
• Factors associated with failure to achieve the intensive blood pressure target in the Systolic Blood Pressure Intervention Trial (SPRINT). Wang KM, et al. Hypertension. 2020;76(6):1725-1733.
• The use of single-pill combinations as first-line treatment for hypertension: Translating guidelines into clinical practice. Campana E, et al. J Hypertens. 2020;38(12):2369-2377.
• SPRINT-A kidney-centric narrative review: Recent advances in hypertension. Hu AH, Chang TI. Hypertension. 2021;78(4):946-954.